Synaffix Licenses Metal-Free Click Chemistry Technology to Illumina for Next-Generation DNA Sequencing Applications
Synaffix announces it has entered into a licensing agreement with Illumina, a global leader in DNA sequencing and array-based technologies. The agreement grants Illumina access to Synaffix’s patented metal-free click chemistry, for next-generation DNA sequencing applications.
Synaffix’s patented metal-free click chemistry will be used in relation to certain Illumina next-generation sequencing (NGS) products. This partnership highlights Synaffix’s commitment to leveraging its innovative technologies to support advancements in large-scale, whole-genome sequencing and make it more accessible.
About Synaffix
Synaffix B.V. is a biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform based on GlycoConnect™, HydraSpace®, and toxSYN® technologies. Together, these technologies enable any company with an antibody to develop proprietary, best-in-class ADC products under a single licence from Synaffix.
Read the full press release here.
Find more news here.